Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2011

View Archived Issues

Frizzled FZD3 receptor expression as a biomarker of CRC and colorectal adenoma

Novel protein kinase inhibitors described at sanofi-aventis

ELGEN-1000-delivered DNA vaccines cleared to enter phase II leukemia trial in U.K.

Genzyme divests diagnostics and pharmaceutical intermediates businesses

Optic nerve sheath CSF flow dynamics as an imaging biomarker of IIH

Scientists generate stable aqueous nanocolloids to improve delivery of anticancer agents

New bombesin BB3 receptor agonist MK-5046 shows preclinical potential to treat obesity

Concert Pharma develops new deuterated GABA(A) receptor modulators

Arena Pharma claims new lysophospholipid S1P1 receptor agonists

Prolia available in Quebec for postmenopausal osteoporosis

Perseid Therapeutics begins phase I trial for CTLA4-Ig program

EMA approves sublingual sildenafil formulation X-Excite for erectile dysfunction

New GPR119 receptor agonists presented

Sinovac Biotech files clinical trial application in China for 23- and 24-valent PPVs

Zymenex's Lamazym advances to phase II in alpha-mannosidosis

Encouraging interim phase II data on Medicago's H5N1 vaccine

Prolor's factor IX-CTP shows promise in model of hemophilia

Isis Pharma begins phase I trial of ISIS-FXIRx for clotting disorders

Enrollment started in Aveo Pharma's phase II tivozanib biomarker trial

Enrollment halted in INSPIRE trial of necitumumab in advanced NSCLC

Temple University divulges new leptin receptor agonists

Sunovion set to launch Latuda in U.S. for schizophrenia

New inhibitors claimed of RAC-alpha serine/threonine-protein kinase phosphorylation

Pegasys/Copegus combination to get priority review in Japan for new indication

Otuska Pharma begins Japanese phase II OCV-101 trial in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...